4.7 Article

Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2

Journal

FASEB JOURNAL
Volume 29, Issue 4, Pages 1577-1590

Publisher

WILEY
DOI: 10.1096/fj.14-265066

Keywords

CGS21680; dipyridamole; bone formation; osteoclast; osteoblast

Funding

  1. U.S. National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR56672, AR54897, AR046121]
  2. NIH National Heart, Lung, and Blood Institute [RC1-HL100815]
  3. New York University Health and Hospitals Corporation (NYU-HHC) Clinical and Translational Science Institute [UL1TR000038]
  4. New York University Caregiver Intervention (NYUCI) Center support grant from NIH National Cancer Institute [5-P30CA16087-310]
  5. Takeda
  6. Celgene
  7. AstraZeneca
  8. Gilead Pharmaceuticals

Ask authors/readers for more resources

Promoting bone regeneration and repair of bone defects is a need that has not been well met to date. We have previously found that adenosine, acting via A(2A) receptors (A2AR) promotes wound healing and inhibits inflammatory osteolysis and hypothesized that A2AR might be a novel target to promote bone regeneration. Therefore, we determined whether direct A2AR stimulation or increasing endogenous adenosine concentrations via purine transport blockade with dipyridamole regulates bone formation. We determined whether coverage of a 3 mm trephine defect in a mouse skull with a collagen scaffold soaked in saline, bone morphogenetic protein-2 (BMP-2; 200 ng), 1 mu M CGS21680 (A2AR agonist, EC50 = 160 nM), or 1 mu M dipyridamole (EC50 = 32 nM) promoted bone regeneration. Microcomputed tomography examination demonstrated that CGS21680 and dipyridamole markedly enhanced bone regeneration as well as BMP-2 8 wk after surgery (60 +/- 2%, 79 +/- 2%, and 75 +/- 1% bone regeneration, respectively, vs. 32 +/- 2% in control, P < 0.001). Blockade by a selective A2AR antagonist (ZM241385, 1 mu M) or deletion of A2AR abrogated the effect of CGS21680 and dipyridamole on bone regeneration. Both CGS21680 and dipyridamole treatment increased alkaline phosphatase-positive osteoblasts and diminished tartrate resistance acid phosphatase-positive osteoclasts in the defects. In vivo imaging with a fluorescent dye for new bone formation revealed a strong fluorescent signal in treated animals that was equivalent to BMP-2. In conclusion, stimulation of A2AR by specific agonists or by increasing endogenous adenosine levels stimulates new bone formation as well as BMP-2 and represents a novel approach to stimulating bone regeneration.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available